SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Social media platforms are seeing a surge in speculative chatter as investors debate the legitimacy of tokenized pre-IPO assets, with many users warning of potential scams while others track news regarding a long-rumored SpaceX public offering. Community members are actively analyzing the aerospace sector, focusing on the potential impact of a high-profile IPO and debating whether current market excitement reflects genuine valuation or a bubble driven by retail FOMO.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is attracting significant attention as investors speculate on its role in the AI-agent infrastructure space, with the community actively discussing potential institutional interest and long-term utility. Despite recent price volatility, supporters are highlighting bullish ecosystem developments and active development as reasons to maintain a long-term position.

Swell

The community is actively debating the potential of Swell, with supporters highlighting its liquid staking utility, institutional backing, and low market cap as key drivers for long-term growth. Conversely, critics frequently dismiss the asset as a speculative project, pointing to recurring price volatility and concerns over supply issuance as reasons for caution.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining momentum as investors weigh its potential as a vertically integrated domestic rare earth magnet manufacturer against concerns regarding its micro-float and high insider ownership. Community discussion is split between excitement over the stock's positioning as a strategic alternative to foreign supply chains and caution regarding its characteristic high volatility and potential for sharp price swings.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

The community is actively discussing $DEGEN, pointing to a mix of optimism surrounding potential exchange listings and a new beta app while others express frustration over token performance. Investors remain hyper-focused on upcoming project catalysts and social media branding as they debate whether the token is currently at a critical accumulation phase.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following an exclusive U.S. supply agreement for the Tokyo strain of BCG to address the ongoing domestic shortage, a move the community views as a strategic breakthrough that strengthens the company's competitive position against major pharmaceutical players. Investors are actively discussing the potential for accelerated regulatory pathways, the synergy between this supply and Anktiva, and the anticipation of further catalysts being revealed at the upcoming American Urological Association conference.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as investors monitor Q4 earnings results and weigh the ongoing growth of immunology blockbusters Skyrizi and Rinvoq against the managed decline of Humira revenues. Meanwhile, community discussions are heavily focused on the company's potential M&A appetite in the obesity and oncology sectors, with retail sentiment remaining vigilant regarding potential competitive threats and pipeline expansion strategies.

WW International, Inc. engages in the provision of weight management services. It operates through the following geographical segments: United States, Germany, and Other. The company was founded by Jean Nidetch in 1963 and is headquartered in New York, NY.

WW International Inc - Ordinary Shares - New

WW International, Inc. Common Stock

WW International is gaining traction as investors speculate on a turnaround driven by strategic partnerships with GLP-1 medication providers and debt-reduction efforts. The community remains divided, with some betting on a successful pivot toward clinical weight-loss solutions while others remain skeptical due to the company's historical financial struggles and competitive pressure.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is experiencing a surge in investor interest driven by strong prescription growth, successful patent protection, and a clear path toward operating profitability in the coming quarters. The community is actively discussing the stock's potential for acquisition by larger pharmaceutical firms, while closely monitoring the ongoing battle against high short interest and institutional accumulation patterns.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render Token is currently capturing significant attention as investors double down on decentralized AI infrastructure and GPU-based compute plays. The community is heavily focused on the protocol's utility in the expanding AI landscape, with many traders actively accumulating positions while discussing its long-term potential compared to other artificial intelligence and DePIN projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kimbell Royalty (KRP) Just Overtook the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Kimbell Royalty (KRP) Q1 Earnings and Revenues Miss Estimates

Kimbell Royalty (KRP) delivered earnings and revenue surprises of -82.36% and -29.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Kimbell Royalty Partners Announces First Quarter 2026 Results

Kimbell Royalty Partners Announces First Quarter 2026 Results Kimbell Royalty Partners Announces First Quarter 2026 Results PR Newswire FORT WORTH, Texas, May 7, 2026 Q1 2026 Run-Rate Daily...

Kimbell Royalty (NYSE:KRP) Receives Consensus Rating of "Hold" from Analysts

Kimbell Royalty (NYSE:KRP - Get Free Report) has received a consensus recommendation of "Hold" from the five brokerages that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the compan...

Kimbell Royalty (NYSE:KRP) Sets New 12-Month High - Here's What Happened

Kimbell Royalty (NYSE:KRP) Reaches New 1-Year High - Here's What Happened...

Implied Volatility Surging for Kimbell Royalty Stock Options

Investors need to pay close attention to KRP stock based on the movements in the options market lately.

Earnings Estimates Rising for Kimbell Royalty (KRP): Will It Gain?

Kimbell Royalty (KRP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Kimbell Royalty (KRP) Earnings Expected to Grow: Should You Buy?

Kimbell Royalty (KRP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kimbell Royalty (KRP) Projected to Post Earnings on Thursday

Kimbell Royalty (NYSE:KRP) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-kimbell-royalty-partners-lp-stock...

Kimbell Royalty (NYSE:KRP) Sets New 1-Year High - Here's What Happened

Kimbell Royalty (NYSE:KRP) Hits New 1-Year High - Time to Buy...

Kimbell Royalty Partners LP engages in owning and acquiring mineral and royalty interests in oil and natural gas properties. Its oil and gas assets include mineral interests and overriding royalty interests. The company was founded by Robert Ravnaas, Robert Davis Ravnaas, Brett G. Taylor, and Mitch S. Wynne on October 30, 2015 and is headquartered in Fort Worth, TX.

KRP
Kimbell Royalty Partners

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest KRP News

KRPKimbell Royalty Partners